VISITING SPEAKERS PROGRAM IN ONCOLOGY
2016-2017
The McGill Continuing Professional Development Office has made available, [webcasts](#) of the presentations.

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Date(s)</th>
<th>Institution</th>
<th>Title(s) of Presentation(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>September – December 2016</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Bertrand Tombal</td>
<td>September 21-22</td>
<td>Université catholique de Louvain, Brussels, Belgium</td>
<td>• Management of mCRPC: Tailoring treatment to the patient</td>
</tr>
<tr>
<td>Dr. Dennis Kim</td>
<td>November 9</td>
<td>Princess Margaret Hospital, Toronto, Ontario, Canada</td>
<td>• Hidden advances and remaining challenges in CML</td>
</tr>
<tr>
<td>Dr. Anand Jillela</td>
<td>November 16-17</td>
<td>Emory University School of Medicine, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA</td>
<td>• New developments and strategies for reducing early death in APL</td>
</tr>
<tr>
<td><strong>January – June 2017</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Richard R. Furman</td>
<td>January 18-20</td>
<td>Weill Cornell Medicine, New York, USA</td>
<td>• Update in the treatment of Chronic Lymphocytic Leukemia</td>
</tr>
<tr>
<td>Dr. Yu Shyr</td>
<td>January 25-26</td>
<td>Vanderbilt University School of Medicine, Nashville, Tennessee, USA</td>
<td>• Statistics in oncology: Navigating clinical trials and putting data into practice</td>
</tr>
<tr>
<td>Pr. Gilles Salles</td>
<td>April 4-7</td>
<td>Université Claude Bernard, Lyon, France</td>
<td>• Revue et nouveautés dans le traitement des Lymphomes Indolents réfractaires ou récidivants</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Review and new developments in refractory or recurrent Indolent Lymphoma</td>
</tr>
<tr>
<td>Dr. Ming-Sound Tsao</td>
<td>May 17-18</td>
<td>University of Toronto, Toronto, Ontario, Canada</td>
<td>• Integrated diagnosis of lung cancer- How can we obtain all the useful diagnostic information with a small biopsy?</td>
</tr>
<tr>
<td>Pr. Pier Luigi Zinzani</td>
<td>May 24-25</td>
<td>University of Bologna, Bologna, Italy</td>
<td>• What is timely treatment initiation in follicular lymphoma and why it matters?!</td>
</tr>
<tr>
<td>Dr. Todd Pawlicki</td>
<td>June 14-15</td>
<td>University of California, San Diego, USA</td>
<td>• Quality Improvement (QI) and patient safety in oncology</td>
</tr>
</tbody>
</table>
**Learning Objectives**

- Discuss the underlying biological rationale for different treatments for patients with metastatic castration-resistant prostate cancer (mCRPC) and their utility in different treatment settings
- Define specific clinical criteria to enable appropriate treatment selection for their patients with mCRPC, based on analysis of the most up to date clinical trials data
- Outline current issues around resistance and other aspects of treatment optimization that may have an impact on future treatment paradigms
Dr Dennis Kim - MD
Associate Professor,
Faculty of Medicine, University of Toronto
Staff Physician/Clinical Investigator,
Department of Medical Oncology & Hematology,
Princess Margaret Hospital
Toronto, Ontario

“Hidden Advances and Remaining Challenges in CML”

Wednesday, November 9, 2016

Glen – Cedars Cancer Centre
Room D02.1312
08:30 to 09:30

Hôpital Notre-Dame
Amphithéâtre Deschamps
17:00 to 18:00

Learning Objectives

• Discuss relevant findings of the PMH CML database in regards to patient management and outcome after TKI therapy
• Exchange on the evolving treatment goals of CML and their clinical implications on patients and physicians’ clinical practice
• Best practice sharing in the management and treatment optimization of sub-optimal CML responders and pre-transplant patients (Case base discussion)

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visiting speakers.asp

This program has received an educational grant from:
Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche
Learning Objectives

- To discuss current recommendations and outcomes in APL therapy, the management of toxicities such as coagulopathy and the role of new treatment options
- To discuss the management of high-risk APL patients, elderly patients and those with comorbidities
- To share treatment algorithm as a strategy to optimize early diagnosis and to reduce early death in APL patients and to discuss its implementation in community hospitals

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp

This program has received an educational grant from:
Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche
Dr Richard R. Furman, M.D.
Director of the CLL Research Center
Member of the Lymphoma/Myeloma Service
Division of Hematology/Oncology
Weill Cornell Medicine, New York

“Update in the treatment of Chronic Lymphocytic leukemia”

Wednesday, January 18, 2017
Glen – Cedars Cancer Centre
Room D02.1312
08:30 to 09:30

Hôpital Maisonneuve-Rosemont
Room 0-80 (Pavillon Marcel Lamoureaux)
12:00 to 13:00

Hôpital Notre-Dame
Amphithéâtre Deschamps
17:00 to 18:00

Thursday, January 19, 2017
Jewish General Hospital
Room E-711
12:30 to 13:30

Hôpital du Sacré-Cœur de Montréal
Room G-4130
15:00 to 16:00

Friday, January 20, 2017
Hôpital Charles Le Moyne
Room HN-106
9:00 to 10:00

Learning Objectives
• To discuss the role of novel agents in the management of frontline CLL and how to approach patient selection
• To consider the evolving role of novel agents in the management of relapsed CLL and how to sequence therapies
• To share experience and best practices of effective management of adverse events associated with novel agents for CLL

Visioconference Request: vspo@mcgill.ca

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seatles Genetics
Dr Yu Shyr, Ph.D.
Harold L. Moses Chair in Cancer Research
Director, Vanderbilt Center for Quantitative Sciences
Director, Vanderbilt Technologies for Advanced Genomics Analysis and Research Design
Professor of Biostatistics, Biomedical Informatics, Cancer Biology and Health Policy
Vanderbilt University School of Medicine

“Statistics in Oncology: Navigating Clinical Trials and Putting Data into Practice”

Wednesday, January 25, 2017

Hôpital de la Cité-de-la-Santé, Laval
Salle GS-011
8:00 to 9:00

Hôpital général juif
Salle E-711
12:00 to 13:00

Hôpital Notre-Dame
Amphithéâtre Deschamps
17:00 to 18:00

Thursday, January 26, 2017

Glen - Cedars Cancer Centre
Salle D03.5039
09:00 to 10:00

Hôpital Charles Le Moyne
Salle HS-0053
12:00 to 13:00

Hôpital du Sacré-Cœur de Montréal
Salle G-4130
15:00 to 16:00

Learning Objectives
• Review of Statistics 101 for Oncology Health Care Professionals
• Understand important statistics you need to know for clinical trials
• Discuss common statistical mistakes in clinical trials
• What does this all mean? Discuss interpreting trial data and putting it into clinical practice

Visioconference Request: vspo@mcgill.ca

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visiting-speakers.asp

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seattle Genetics
LEARNING OBJECTIVES

At the end of the session, the participant will be able to:

• Identify the biological and clinical factors influencing treatment initiation as well as the choice of treatment for patients with relapsed or refractory disease.
• Recognize the indication and management of toxicities associated with new available therapies.
• Identify new future therapies for this population.

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seattle Genetics
DR. MING-SOUND TSAO, FRCPC, MD

Thoracic Pathologist and Senior Scientist
Princess Margaret Cancer Centre
Professor of Laboratory Medicine and Pathobiology,
and the M. Qasim Choksi Chair in Lung Cancer Translational Research
University of Toronto, Canada

INTEGRATED DIAGNOSIS OF LUNG CANCER - HOW CAN WE OBTAIN ALL THE USEFUL DIAGNOSTIC INFORMATION WITH A SMALL BIOPSY?

WEDNESDAY, MAY 17, 2017

Hôpital Charles -Le Moyne
Room HN-106
12:00 to 13:00
Videoconference Request: vspo@mcgill.ca

Hôpital Notre-Dame
Amphithéâtre Deschamps
17:00 to 18:00

THURSDAY, MAY 18, 2017

MUHC-GLEN
Room D03.6020
9:00 to 10:00
Videoconference Request: vspo@mcgill.ca

Jewish General Hospital
Room H-433
12:00 to 13:00
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

LEARNING OBJECTIVES

• To understand the importance of molecular testing in the diagnosis and management of NSCLC
• To be familiarized with new technologies that allow for more comprehensive molecular diagnoses
• To appreciate how quantity of tissue impacts the molecular testing that can be done, and the trade-offs with minimizing procedural risks to patients
• To discuss ways that ensure maximal diagnostic value is obtained when limited tissue is available

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visiting-speakers.asp

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seattle Genetics, Shire
PIER LUIGI ZINZANI, MD, PHD
Professor of Hematology
Institute of Hematology "L. e A. Seràgnoli"
University of Bologna
Bologna, Italy

WHAT IS TIMELY TREATMENT INITIATION IN FOLLICULAR LYMPHOMA AND WHY IT MATTERS?!

WEDNESDAY, MAY 24, 2017
Glen – Cedars Cancer Centre
Room D02.1312
08:30 to 09:30
Visioconference Request: vspo@mcgill.ca

Hôpital Notre-Dame
Amphithéâtre Deschamps
17:00 to 18:00
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

THURSDAY, MAY 25, 2017
Jewish General Hospital
Room E-711
12:30 to 13:30
Visioconference Request: vspo@mcgill.ca

LEARNING OBJECTIVES

• Describe current initial treatment paradigms and associated outcomes for follicular lymphoma
• Review current evidence regarding the prognostic factors/biomarkers in support of timely treatment initiation
• Determine the key aspects of the clinician-patient communications related to treatment and its initiation

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visiting speakers.asp

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seatles Genetics, Shire Oncology
This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seattle Genetics, Shire Oncology
McGill Radiation Oncology, McGill Medical Physics

LEARNING OBJECTIVES
At the conclusion of the activity, participants will be able to:
• Understand the principles of Quality Improvement initiatives and how to start implementing projects in their own departments
• Recognize factors leading to errors in practice and how to establish a positive safety culture in their own department
• Design systems to evaluate practice and safety by using techniques such as systems theory and process control

WEDNESDAY, JUNE 14, 2017
GLEN - CEDARS CANCER CENTRE
Room DS1.1427
12:00 to 13:00
Videoconference Request: vspo@mcgill.ca
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

THURSDAY, JUNE 15, 2017
HÔPITAL NOTRE-DAME
Pavillon Lachapelle
Room TS-4288
12:30 to 13:30

DR. TODD PAWLICKI, PHD, FAAPM
Professor and Vice-Chair of Medical Physics
Division Director
Department of Radiation Medicine and Applied Sciences
University of California, San Diego

"QUALITY IMPROVEMENT (QI) AND PATIENT SAFETY IN ONCOLOGY"